• Lifeloc Technologies posted a narrower net loss of $152,713 for the quarter ended March 31, 2026, improving 48% year over year.
• Net sales rose 1% to $2.29 million, with total revenues up 1% to $2.29 million.
• Gross profit climbed 9% to $987,074, lifting product gross margin by 3 percentage points to 43%.
• Research, development and sustaining engineering expenses fell 12% to $414,445, while sales and marketing costs dropped 6% to $313,229.
• Commercial launch of SpinDetect drug-testing platform remains expected in 2026, with beta testing under way for an oral-fluid analyzer focused on delta-9-THC detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeloc Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001553350-26-000075), on May 14, 2026, and is solely responsible for the information contained therein.